Evidence map›Paper›PMID 42825379›Full record

ArticleOncology reports2026

Targeting the DNHD1‑HDAC6 axis inactivates prostate cancer cell aggressiveness

An Ni Lee, Chia Chang Wu, Su Wei Hu, Chih Heng Chen, Yi Te Chiang, Wei Tang Kao, Kai Yi Tzou, Chia Hung Liu, Shao Wei Dong, Yu Ting Wang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

An Ni LeeDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 23561, R.O.C.
Chia Chang WuDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 23561, R.O.C.
Su Wei HuDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 23561, R.O.C.
Chih Heng ChenDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 23561, R.O.C.
Yi Te ChiangDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 23561, R.O.C.
Wei Tang KaoDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 23561, R.O.C.
Kai Yi TzouDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 23561, R.O.C.
Chia Hung LiuDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 23561, R.O.C.
Shao Wei DongDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 23561, R.O.C.
Yu Ting WangDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 23561, R.O.C.
Yueh Lin LeeDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 23561, R.O.C.
Siou Bi LiDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 23561, R.O.C.
Che An WuDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 23561, R.O.C.
Chiao Chun LiaoDepartment of Tropical Medicine, School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan 300093, R.O.C.
Ming Hsien ChanDepartment of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei 112, Taiwan 300093, R.O.C.
Po Han ChiuDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 23561, R.O.C.
Chien Hsiu LiDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 23561, R.O.C.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer progression toward an aggressive, therapy‑resistant disease state remains a major clinical challenge, indicating a need to identify novel molecular drivers of such progression and actionable therapeutic targets. The present study analyzed the role of dynein heavy chain domain 1 (

Indexed as

Histone Deacetylase 6Prostatic NeoplasmsAnimalsBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansHydroxamic AcidsIndolesMalePrognosisSignal TransductionBiomarkers, TumorHDAC6 protein, humanHistone Deacetylase 6Hydroxamic AcidsIndolestubastatin Abioinformaticdynein heavy chain domain 1histone deacetylase 6prognosisprostate cancer

Identifiers

PMID42825379
PMCPMC13659732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.